Improving immune tolerance treatment in severe hemophilia A with inhibitors
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a new approach to immune tolerance induction (ITI) in young people with severe hemophilia A who have a high-titer inhibitor. It uses a specific clotting factor combined with emicizumab to try to retrain the immune system so that standard treatments work again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Severe hemophilia A (a bleeding disorder where the body doesn't make enough of a specific clotting protein)
- High-titer inhibitor: a blood test showing the immune system blocks usual treatment (higher than a set limit)
- Under 18 years old at the start of the study
- Currently on your first immune tolerance induction (ITI) treatment, which uses regular clotting factor to try to stop the inhibitor
- Currently using or planning to use emicizumab (a medicine that works in a different way to prevent bleeding)
- No other bleeding disorders, no prior ITI course, and no history of blood clots without a clear cause
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a therapy called ITI (using SCT800 alone or with daratumumab) to help people with hemophilia A who have inhibitor antibodies that reduce bleeding treatments from working. It may be an option if you’re an adolescent or adult with a high inhibitor level and have not already failed this kind of immune “ITI” treatment before.
This study collects real-world information on how well a personalized clotting-factor plan helps people with hemophilia A get rid of inhibitors. It may help doctors refine treatment for patients who develop antibodies that block factor therapy.
This trial studies how your body’s anti-factor VIII antibodies change while you are treated with emicizumab for severe hemophilia A. The goal is to better understand the immune response during treatment and whether it relates to how well therapy works.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
This study tests a new medicine called SKP-0141 to see if it can safely treat and prevent bleeding in people with severe hemophilia A. It might help reduce the number of bleeds and improve quality of life.
This study tests a new treatment (FRSW107) for severe hemophilia A in children under 12. It aims to see if this treatment is safe and helps prevent bleeding episodes.
Hear when a new Hemophilia A With Inhibitor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.